|
시장보고서
상품코드
2032929
췌장암 치료제 및 진단약 시장 보고서 : 유형별, 용도별, 지역별(2026-2034년)Pancreatic Cancer Therapeutics and Diagnostics Market Report by Type (Diagnostics, Treatment), Application (Hospitals, Clinics, and Others), and Region 2026-2034 |
||||||
세계의 췌장암 치료제 및 진단약 시장 규모는 2025년에 48억 달러에 이르렀습니다. IMARC Group은 향후 2026-2034년 CAGR 5.94%로 성장을 지속하여, 2034년까지 시장 규모가 82억 달러에 이를 것으로 예측했습니다. 급성장하는 헬스케어 산업, 췌장암 유병률 증가, 췌장암 세포를 죽이기 위한 화학요법에 대한 수요 증가 등이 시장을 이끄는 주요 요인으로 작용하고 있습니다.
췌장암 치료제 및 진단약이란 췌장암을 진단하고 치료하기 위해 사용되는 의료 행위를 말합니다. 이러한 치료 및 진단 방법에는 초음파 검사, 컴퓨터 단층촬영(CT) 스캔, 자기공명영상(MRI), 양전자방출단층촬영(PET) 스캔 등이 있습니다. 이는 초음파 장비를 이용해 복강 내에서 췌장 영상을 촬영하는 내시경적 초음파 검사(EUS)에 의존하고 있습니다. 이는 췌장 내 세포가 통제할 수 없을 정도로 증식하여 종양의 위치를 감시하는 데 도움이 됩니다. 또한 현미경으로 검사하기 위해 조직의 작은 샘플을 채취하는 생검을 시행할 수 있도록 지원합니다. 또한, 전혈구검사(CBC), 담도폐색 여부를 확인하는 간효소 검사, 공복혈당 및 글리코헤모글로빈(HbA1c) 검사 등의 임상검사도 도움이 됩니다. 그 결과, 췌장암의 치료 및 진단법은 전 세계 병원과 전문 의료센터에서 활용되고 있습니다.
췌장암 치료제 및 진단약 시장 동향 :
현재 고령화 진행과 일반인의 과도한 흡연 습관으로 인한 췌장암 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 이 외에도 전 세계적으로 분자생물학, 의약품, 진단 기술 개발이 진행되고 있습니다. 이는 호황을 누리고 있는 헬스케어 산업과 맞물려 현재 시장 성장을 견인하고 있습니다. 또한, 췌장암 세포의 증식과 분열을 막아 사멸시키는 화학요법에 대한 수요 증가도 시장에 긍정적인 영향을 미치고 있습니다. 또한, 많은 국가의 규제 당국은 췌장암 임상시험과 화학요법과 결합된 데옥시리보핵산(DNA) 복구 억제제에 대한 투자를 적극적으로 진행하고 있습니다. 또한, 임상 단계에 있는 약물의 승인을 통해 췌장암 치료제 및 진단약물의 성장 촉진에도 주력하고 있습니다. 이와 별도로, 업계 주요 기업들은 식도암, 위식도 접합부암, 췌장암 치료를 위해 항종양 면역반응을 촉진하는 인간화 단일클론항체를 도입하고 있습니다. 또한, BRCA1과 BRCA2의 변이를 확인하고 유전체 불안정성을 평가하여 췌장암을 검출하는 키트 기반 검사를 개발 및 도입하고 있으며, 이는 향후 몇 년 동안 시장 성장에 기여할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 세계 췌장암 치료제 및 진단약 시장은 지금까지 어떤 추세를 보였습니까? 또한 향후 몇 년 동안 어떤 추이가 예상되나요?
- 세계 췌장암 치료제 및 진단약 시장 성장 촉진요인, 제약 요인 및 기회는 무엇일까요?
- 주요 지역 시장은?
- 가장 매력적인 췌장암 치료제 및 진단약 시장을 형성하고 있는 국가는 어디인가요?
- 시장 유형별 시장 내역은?
- 췌장암 치료제 및 진단약 시장에서 가장 매력적인 유형은 무엇일까요?
- 용도별 시장 현황은?
- 췌장암 치료제 및 진단약 시장에서 가장 매력적인 용도는?
- 세계 췌장암 치료제 및 진단약 시장 경쟁 구도는 어떤가?
- 세계 췌장암 치료제 및 진단약 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위 및 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 췌장암 치료제 및 진단약 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 지역별
제9장 촉진요인, 억제요인 및 기회
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
AJY 26.05.19The global pancreatic cancer therapeutics and diagnostics market size reached USD 4.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.94% during 2026-2034. The burgeoning healthcare industry, rising prevalence of pancreatic cancer, and the escalating demand for chemotherapy to kill pancreatic cancer cells represent some of the key factors driving the market.
Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) , and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas. They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.
PANCREATIC CANCER THERAPEUTICS AND DIAGNOSTICS MARKET TRENDS:
At present, the rising prevalence of pancreatic cancer due to the increasing geriatric population and excessive smoking habits among the masses represents one of the key factors supporting the growth of the market. Besides this, there is an increase in the development of molecular biology, drugs, and diagnostic technology around the world. This, along with the thriving healthcare industry, is currently propelling the growth of the market. In addition, the escalating demand for chemotherapy to kill pancreatic cancer cells by preventing them from growing and dividing is positively influencing the market. Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.
KEY MARKET SEGMENTATION:
Type Insights:
- Diagnostics
- Imaging
- Biopsy
- Endoscopic Ultrasound
- Others
- Treatment
- Targeted Therapies
- Chemotherapy
- Surgery
- Others
Application Insights:
- Hospitals
- Clinics
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global pancreatic cancer therapeutics and diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies include AstraZeneca plc, F. Hoffmann-La Roche Ltd., Immunovia AB, Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global pancreatic cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global pancreatic cancer therapeutics and diagnostics market?
- What are the key regional markets?
- Which countries represent the most attractive pancreatic cancer therapeutics and diagnostics markets?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the pancreatic cancer therapeutics and diagnostics market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the pancreatic cancer therapeutics and diagnostics market?
- What is the competitive structure of the global pancreatic cancer therapeutics and diagnostics market?
- Who are the key players/companies in the global pancreatic cancer therapeutics and diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pancreatic Cancer Therapeutics and Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Diagnostics
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Imaging
- 6.1.2.2 Biopsy
- 6.1.2.3 Endoscopic Ultrasound
- 6.1.2.4 Others
- 6.1.3 Market Forecast
- 6.2 Treatment
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Targeted Therapies
- 6.2.2.2 Chemotherapy
- 6.2.2.3 Surgery
- 6.2.2.4 Others
- 6.2.3 Market Forecast
7 Market Breakup by Application
- 7.1 Hospitals
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Clinics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
- 9.1 Overview
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 AstraZeneca plc
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 F. Hoffmann-La Roche Ltd.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Immunovia AB
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Novartis AG
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.1 AstraZeneca plc
